Epidemiology

  • Incidence: 3.00 cases per 100,000 person-years
  • Peak incidence: 70+ years
  • Sex ratio: more common in males 3:1
Condition Relative
incidence
Lung cancer25.67
Mesothelioma1
<1 1-5 6+ 16+ 30+ 40+ 50+ 60+ 70+ 80+

Clinical features

Features
  • Dyspnoea, weight loss, chest wall pain
  • Clubbing
  • 30% present as painless pleural effusion
  • Only 20% have pre-existing asbestosis
  • History of asbestos exposure in 85-90%, latent period of 30-40 years

Referral criteria

NICE cancer referral guidelines for mesothelioma suggest the following:


Refer people using a suspected cancer pathway referral (for an appointment within 2 weeks) for mesothelioma if they have chest X‑ray findings that suggest mesothelioma.

Offer an urgent chest X‑ray (to be performed within 2 weeks) to assess for mesothelioma in people aged 40 and over, if:
  • they have 2 or more of the following unexplained symptoms, or
  • they have 1 or more of the following unexplained symptoms and have ever smoked, or
  • they have 1 or more of the following unexplained symptoms and have been exposed to asbestos:
    • cough
    • fatigue
    • shortness of breath
    • chest pain
    • weight loss
    • appetite loss.

Consider an urgent chest X‑ray (to be performed within 2 weeks) to assess for mesothelioma in people aged 40 and over with either:
  • finger clubbing or
  • chest signs compatible with pleural disease.

Investigations

Investigation/diagnosis
  • suspicion is normally raised by a chest x-ray showing either a pleural effusion or pleural thickening
  • the next step is normally a pleural CT
  • if a pleural effusion is present fluid should be sent for MC&S, biochemistry and cytology (but cytology is only helpful in 20-30% of cases)
  • local anaesthetic thoracoscopy is increasingly used to investigate cytology negative exudative effusions as it has a high diagnostic yield (around 95%)
  • if an area of pleural nodularity is seen on CT then an image-guided pleural biopsy may be used

Management

Management
  • Symptomatic
  • Industrial compensation
  • Chemotherapy, Surgery if operable
  • Prognosis poor, median survival 12 months